Hi @Gilant, I can't as it is their IP. They did recommend it.
Recommendation: Speculative Buy Class A
Which means, these stocks will have more than one technology, product orinvestment in development, with perhaps those same technologiesoffering multiple opportunities. These features, coupled to thepresence of alliances, partnerships and scientific advisory boards,indicate the stock is relatively less risky than other biotech stocks.
I would get in contact with Hawkesbury Partners and see if they can get you any research.
